Snapshot
Guardant Health, Inc. reported $302M of revenue in Q1 2026, up 48.3% year over year, with diluted EPS of $-0.85 and an operating margin of -40.2%.
- Revenue
- $302M
- YoY growth
- +48.3%
- Diluted EPS
- $-0.85
- Operating margin
- -40.2%
$302M
Revenue
+48.3%
YoY growth
$-0.85
Diluted EPS
-40.2%
Operating margin
01 Key takeaways
What management said
- •Notably, our commercial flywheel has achieved a new level of velocity, delivering our fastest year-over-year percentage revenue growth in the last five years and surpassing the $1 billion trailing 12-month revenue milestone.
- •Patient outcomes like this are one of the many reasons we have benefited from accelerating adoption and growth.
- •Turning to our revenue performance in slide four, we had a phenomenal start to 2026, delivering $302 million of revenue in Q1, representing 48% year-over-year growth.
- •The growth was strong and broad-based across our oncology, biopharma and data, and screening business lines.
- •Taking a closer look at our oncology business in slide five, oncology revenue growth accelerated to 36% year-over-year, driving Q1 revenue of $205 million.
- •This was the highest year-over-year percentage growth in oncology volume we've seen in nearly three years, with strength across all products.
- •Turning to slide six, our 47% year-over-year volume growth reflects the increasing breadth of our portfolio across both therapy selection and MRD.
- •Guardant360 Liquid delivered 30% volume growth year-over-year, while Guardant360 Tissue was our second fastest-growing product.
- •Smart Platform innovation continues to translate directly into volume growth for both products, with InfinityAI powering a steady cadence of new clinical applications that are driving deeper adoption among oncologists.
- •We have a strong pipeline of additional Smart Apps in development, and we look forward to continuing that cadence.
- •The result is a compounding flywheel wherein data drives better insights, which in turn fuels volume growth and strengthens our data advantage.
- •Turning to slide eight to take a closer look at our Reveal data pipeline.
SourcesCompany financials · earnings call
Last updated